FCPM III Services B.V.
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 8, 2024), FCPM III Services B.V. reported 7 stock positions worth $678.1 million. Its top holding was Dyne Therapeutics (DYN) at 40.8% of the portfolio, followed by Newamsterdam Pharma (NAMS, 33.5%) and Engene (ENGN, 12.1%). Compared with Q1 2024, it opened 1 new position. The biggest buy was a new position in Bicycle Therapeutics PLC-ADR (BCYC).
- Most Recent 13F
- Q2 2026
- Location
- NAARDEN, P7
- CIK
- 0002013410
- Portfolio Value
- $678.1M (Q2 2024)
- SEC Filing
- 0001802806-24-000036 ↗ filed Aug 8, 2024
Holdings Value
Holdings 7 stocks · $678.1M
| DYN Dyne Therapeutics Inc. | 40.83% | 7,845,364 | $276.9M | No change |
| NAMS Newamsterdam Pharma Co. NV | 33.52% | 11,831,461 | $227.3M | No change |
| ENGN Engene Holdings Inc. | 12.07% | 8,677,951 | $81.8M | No change |
| REPL Replimune Group Inc. | 6.46% | 4,866,449 | $43.8M | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 6.34% | 2,122,892 | $43.0M | New |
| ENGENE HOLDINGS INC | 0.51% | 2,878,148 | $3.4M | No change |
| ACHL Achilles Therapeutics PL-ADR | 0.29% | 2,390,050 | $1.9M | No change |
Portfolio Sells Q1 2024 → Q2 2024
| None this quarter. | |||
Portfolio Buys Q1 2024 → Q2 2024
| BCYC Bicycle Therapeutics PLC-ADR | New | 6.34% | +6.34 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 11 | $750.4M | NAMS, MPLT, DYN, VOR, DMRA |
| Q1 2026 | 10 | $722.2M | NAMS, DYN, VOR, ENGN, MPLT |
| Q4 2025 | 10 | $762.9M | NAMS, DYN, ENGN, RAPT, MPLT |
| Q3 2025 | 9 | $500.4M | NAMS, DYN, ENGN, ATXS, BCYC |
| Q2 2025 | 8 | $369.2M | NAMS, DYN, REPL, ENGN, BCYC |
| Q1 2025 | 7 | $413.7M | NAMS, DYN, ENGN, REPL, BCYC |
| Q4 2024 | 8 | $592.4M | NAMS, DYN, ENGN, BCYC, REPL |
| Q3 2024 | 7 | $582.3M | DYN, NAMS, ENGN, REPL, BCYC |
| Q2 2024 | 7 | $678.1M | DYN, NAMS, ENGN, REPL, BCYC |
| Q1 2024 | 6 | $707.3M | NAMS, DYN, ENGN, REPL, ENGENE HOLDINGS INC |